Clinical Trial Update: Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating LY01011 and Xgeva in patients with bone metastases from solid tumors; efficacy and safety data are forthcoming.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases From Solid Tumors

Drugs mentioned

• LY01011
• Xgeva (denosumab)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Bone Metastases From Solid Tumors | Phase 3 | Status: UNKNOWN